Стратегии снижения регоспитализации у пациентов с расстройствами шизофренического спектра, коморбидных наркологической патологии

Полный текст:   Только для подписчиков

Рекомендуемое оформление библиографической ссылки:

Дмитриева С.А., Костюк Г.П. Стратегии снижения регоспитализации у пациентов с расстройствами шизофренического спектра, коморбидных наркологической патологии // Российский психиатрический журнал. 2025. №5. С. 26-37.

Аннотация

В проспективном катамнестическом исследовании с целью изучения современных тактик ведения пациентов с расстройствами шизофренического спектра, отягощенных коморбидной наркологической патологией, для разработки стратегий минимизации риска регоспитализации было обследовано 140 пациентов. Были сформированы когорты пациентов в зависимости от тактики лечения. Для оценки влияния различных терапевтических тактик на риск повторной госпитализации у пациентов с коморбидными психическими расстройствами был применен анализ выживаемости по Каплану-Мейеру. Проведенное исследование подтвердило высокую частоту регоспитализаций среди пациентов с расстройствами шизофренического спектра и коморбидными аддиктивными расстройствами. Было выявлено, что длительная госпитализация снижает риск регоспитализации пациентов с двойным диагнозом. Изолированные фармакологические коррекции не показали существенного влияния на регоспитализацию. Показали тенденцию к статистически значимым такие тактики ведения пациентов как назначение зуклопентиксола-депо и повышение его дозировки.

Ключевые слова психиатрия; шизофрения; психоактивные вещества; регоспитализация; двойной диагноз

Литература

1. Chugunov DA, Shmilovich AA. Pervichnye i vtorichnye negativnye rasstroistva pri shizofrenii – aktual'naya problema sovremennoi klinicheskoi psikhiatrii. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2022. T;122(8):41–7. (In Russ.) DOI 10.17116/jnevro202212208141. EDN ZGPUUJ 2. Fastovtsov GN, Oskolkova SN. Problemy diagnostiki shizofrenii u bol'nykh, potreblyayushchikh PAV. Klinicheskaya psikhiatriya. 2015;13(4):34–9. (In Russ.) 3. Sivolap YuP, Yanushkevich MV, Savchenkov VA. Dvoinoi diagnoz: shizofreniya i zloupotreblenie PAV. Zhurnal nevrologii i psikhiatrii. 2013;5:45–50. (In Russ.) 4. Dobrovol'skaya AE, Sofronov AG. Shizofreniya, otyagoshchennaya addiktivnymi rasstroistvami. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2014;114(6):55–60. (In Russ.) 5. Large M, Mullin K, Gupta P, Harris A, Nielssen O. Systematic meta-analysis of outcomes associated with psychosis and co-morbid substance use. Aust N Z J Psychiatry. 2014 May;48(5):418–32. DOI: 10.1177/0004867414525838. Epub 2014 Mar 3. PMID: 24589980 6. Carrà G, Johnson S, Bebbington P, Angermeyer MC, Heider D, Brugha T, Azorin JM, Toumi M. The lifetime and past-year prevalence of dual diagnosis in people with schizophrenia across Europe: findings from the European Schizophrenia Cohort (EuroSC). Eur Arch Psychiatry Clin Neurosci. 2012 Oct;262(7):607–16. DOI: 10.1007/s00406-012-0305-z. Epub 2012 Mar 17. PMID: 22427152 7. Rosstat. Zdravookhranenie v Rossii. 2016. Moscow: Rosstat, 2017. 170 p. (In Russ.) 8. Drapkina OM, Shutov AM, Efremova EV. Komorbidnost', mul'timorbidnot', dvoinoi diagnoz – sinonimy ili raznye ponyatiya? Kardiovaskulyarnaya terapiya i profilaktika. 2019;18(2). (In Russ.) DOI: 10.15829/1728-8800-2019-2-65-69 9. Mueser KT, Drake RE, Wallach MA. Dual diagnosis: a review of etiological theories. Addict Behav. 1998 Nov-Dec;23(6):717–34. PMID: 9801712 10. Ivanets NN, Vinnikova MA, Ezhkova EV, Tipkov MS, Bulatova RA. Osobennosti kliniki i terapii sindroma zavisimosti ot neskol'kikh PAV u bol'nykh shizofreniei. Narkologiya. 2018;17(5):45–52. (In Russ.) 11. Mendelevich VD. Rukovodstvo po addiktologii. Saint-Petersburg: Rech', 2007. 480 р. (In Russ.) 12. Gouzoulis-Mayfrank E. Doppeldiagnose Psychose und Sucht: Grundlagen und Therapie. Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie 2008;36(4):245–53. DOI: 10.1024/1422-4917.36.4.245 13. Chambers RA, Krystal JH, Self DW. A neurobiological basis for substance abuse comorbidity in schizophrenia. Biol Psychiatry. 2001 Jul 15;50(2):71–83. DOI: 10.1016/s0006-3223(01)01134-9. PMID: 11526998; PMCID: PMC2913410 14. Smith J, Hucker S. Schizophrenia and substance abuse. Br J Psychiatry. 1994 Jul;165(1):13–21. DOI: 10.1192/bjp.165.1.13. PMID: 7953023 15. Hambrecht M, Häfner H. Substance abuse and the onset of schizophrenia. Biol Psychiatry. 1996 Dec 1;40(11):1155–63. DOI: 10.1016/S0006-3223(95)00609-5. PMID: 8931919 16. D'Souza DC, Gil RB, Madonick S, Perry EB, Forselius-Bielen K, Braley G, Donahue L, Tellioglu T, Zimolo Z, Gueorguieva R, Krystal JH. Enhanced sensitivity to the euphoric effects of alcohol in schizophrenia. Neuropsychopharmacology. 2006 Dec;31(12):2767–75. DOI: 10.1038/sj.npp.1301207. Epub 2006 Sep 20. PMID: 16985503 17. Colins O, Vermeiren R, Vahl P, Markus M, Broekaert E, Doreleijers T. Psychiatric disorder in detained male adolescents as risk factor for serious recidivism. Can J Psychiatry. 2011 Jan;56(1):44–50. DOI: 10.1177/070674371105600108. PMID: 21324242 18. Ezhkova EV. Sindrom zavisimosti ot PAV u bol'nykh s komorbidnoi patologiei shizofrenicheskogo spektra: kliniko-dinamicheskie osobennosti, terapevticheskie podkhody [dissertation]. 2021. 204 р. (In Russ.) EDN NCTPRB. 19. Sivolap YuP, Krupitskii EM, Mendelevich VD, et al. Dvoinoi diagnoz: «depressiya» i «rasstroistvo upotrebleniya alkogolya». Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2021;121(7):135–40. (In Russ.) DOI: 10.17116/jnevro2021121071135. EDN JNYYUU 20. Bersani G, et al. Cannabis and schizophrenia: impact on onset, course, psychopathology and outcomes. European Archives of Psychiatry and Clinical Neuroscience. 2012;262:117–23. 21. Bradizza CM, Stasiewicz PR. Qualitative analysis of high-risk drug and alcohol use situations among severely mentally ill substance abusers. Addict Behav. 2003 Jan-Feb;28(1):157–69. DOI: 10.1016/s0306-4603(01)00272-6. PMID: 12507534 22. DeRosse P, Kaplan A, Burdick KE, Lencz T, Malhotra AK. Cannabis use disorders in schizophrenia: effects on cognition and symptoms. Schizophr Res. 2010 Jul;120(1-3):95–100. DOI: 10.1016/j.schres.2010.04.007. Epub 2010 May 18. PMID: 20483565; PMCID: PMC2902262 23. Alderson HL, Semple DM, Blayney C, Queirazza F, Chekuri V, Lawrie SM. Risk of transition to schizophrenia following first admission with substance-induced psychotic disorder: a population-based longitudinal cohort study. Psychol Med. 2017 Oct;47(14):2548–55. DOI: 10.1017/S0033291717001118. Epub 2017 May 3. PMID: 28464965 24. Sofronov AG, Dobrovol'skaya AE, Pashkovskii VE. Polinarkotizatsiya kak patoplasticheskii faktor, vliyayushchii na proyavleniya rasstroistv shizofrenicheskogo spektra. Psikhiatriya. 2019;21(2):78–85. (In Russ.) 25. McLoughlin BC, Pushpa-Rajah JA, Gillies D, et al. Cannabis and schizophrenia. Cochrane Database of Systematic Reviews. 2014;10:CD004837. 26. Barch DM, Celedón JM. Cognitive Deficits in Schizophrenia: A Review of the Literature and Implications for Treatment. Clinical Psychology Review. 2006;26(8):1030–45. 27. Antsyborov AV, Dubatova IV. Problema dvoinykh diagnozov v psikhiatrii i narkologii: ukhodyashchaya real'nost', ili Etap integratsii? Interactive Science. 2019;3(37):35. (In Russ.) 28. Brown J, Vaughn C. Family Therapy and Social Adaptation in Chronic Mental Disorders. London: Routledge; 1999. 210 p. 29. Neznanov NG, et al. Osobennosti komorbidnosti shizofrenii i alkogol'noi zavisimosti v rossiiskoi populyatsii. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2022;122(5):34–42. (In Russ.) DOI: 10.17116/jnevro202212205134 30. Semenyak IV, Shilova EV. Problema psikhicheskogo zdorov'ya patsientov s «dvoinym diagnozom». In: Priverzhennost' voprosam psikhicheskogo zdorov'ya: materialy III Mezhdunarodnoi nauchno-prakticheskoi konferentsii, Moskva, 05–07 oktyabrya 2022 goda. Moscow: Rossiiskii universitet druzhby narodov (RUDN); 2022. Р. 600–606. (In Russ.) EDN KBSSPF 31. Mendelevich VD. Fenomenologiya addiktivnogo vlecheniya: ot differentsiatsii k adekvatnoi terapii. Narkologiya. 2015;14(7):45–50. (In Russ.) 32. Stephen Rich J, Martin PR. Co-occurring psychiatric disorders and alcoholism. Handb Clin Neurol. 2014;125:573–88. DOI: 10.1016/B978-0-444-62619-6.00033-1. PMID: 25307597 33. Dmitrieva SA. Komorbidnost' shizofrenii i narkologicheskoi patologii. Psikhicheskoe zdorov'e cheloveka i obshchestva. In: Aktual'nye mezhdistsiplinarnye problemy i vozmozhnye puti resheniya: Sbornik materialov 8-i Vserossiiskoi nauchno-prakticheskoi konferentsii, Moskva, 30 oktyabrya 2023 goda. Moscow. Izdatel'skii dom KDU; 2024. Р. 422–426. (In Russ.) EDN: YZUJIC 34. Tiet QQ, Mausbach B. Treatments for patients with dual diagnosis: a review. Alcohol Clin Exp Res. 2007 Apr;31(4):513–36. DOI: 10.1111/j.1530-0277.2007.00336.x. PMID: 17374031 35. Ziedonis DM. Integrated treatment of co-occurring mental illness and addiction: clinical intervention, program, and system perspectives. CNS Spectr. 2004 Dec;9(12):892–904, 925. DOI: 10.1017/s1092852900009718. PMID: 15618940 36. Green AI, et al. Substance abuse in schizophrenia: Pharmacotherapeutic intervention. Journal of Clinical Psychopharmacology. 2008;28(6):181–8. 37. Mueser KT, et al. Treatment of Co-Occurring Psychotic and Substance Use Disorders. Schizophrenia Bulletin. 2013;39(3):493–6. 38. Vinnikova MA, Ezhkova EV. Atipichnye antipsikhotiki v terapii bol'nykh s «dvoinym diagnozom». In: Mezhdistsiplinarnye podkhody k izucheniyu psikhicheskogo zdorov'ya cheloveka i obshchestva: materialy nauchno-prakticheskoi konferentsii, Moskva, 29 oktyabrya 2018 goda. Tom 2. Moscow: Izdatel'skii dom KDU; 2019. Р. 285–296. (In Russ.) EDN: CVCWZX 39. Stanovaya VV. A clinical case of the use of cariprazine in therapeutically resistant paranoid schizophrenia comorbid with addictive disorder. Sovremennaya terapiya psihicheskih rasstrojstv. 2020;4:47–52. 40. Csehi R. Real-Life Clinical Experience With Cariprazine: A Systematic Review of Case Studies. Front Psychiatry. 2022;13. DOI: 10.3389/ fpsyt.2022.827744 41. Ricci V, Di Salvo G, Maina G. Remission of persistent methamphetamine-induced psychosis after cariprazine therapy: presentation of a case report. J Addict Dis. 2022;40(1):145–8. DOI: 10.1080/10550887.2021.1945398 42. Semenyak IV, Shilova EV. Problema psikhicheskogo zdorov'ya patsientov s «dvoinym diagnozom». In: Priverzhennost' voprosam psikhicheskogo zdorov'ya: materialy III Mezhdunarodnoi nauchno-prakticheskoi konferentsii, Moskva, 05–07 oktyabrya 2022 goda. Moscow: Rossiiskii universitet druzhby narodov (RUDN); 2022. Р. 600–6. (In Russ.) EDN: KBSSPF 43. Stanovaya VV, Shamanina MV, Ivanov MV, et al. Klinicheskii sluchai primeneniya kariprazina pri terapevticheski rezistentnoi paranoidnoi shizofrenii komorbidnoi s addiktivnym rasstroistvom. Sovremennaya terapiya psikhicheskikh rasstroistv. 2020;4:47–52. (In Russ.) DOI: 10.21265/PSYPH.2020.27.12.006. EDN AERZDE 44. Mendelevich VD. Psikhiatriya v epokhu addiktologii: novye diagnosticheskie i terapevticheskie realii. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2021;121(5):12–8. (In Russ.) DOI: 10.17116/jnevro202112105112 45. Sivolap YuP. Zloupotreblenie alkogolem i farmakoterapiya alkogolizma. Rossiiskii meditsinskii zhurnal. 2014;22(12):45–50. (In Russ.) 46. Yoshimura A, Kimura M, Nakayama H, Matsui T, Okudaira F, Akazawa S, Ohkawara M, Cho T, Kono Y, Hashimoto K, Kumagai M, Sahashi Y, Roh S, Higuchi S. Efficacy of disulfiram for the treatment of alcohol dependence assessed with a multicenter randomized controlled trial. Alcohol Clin Exp Res. 2014 Feb;38(2):572–8. DOI: 10.1111/acer.12278. Epub 2013 Oct 11. PMID: 24117666 47. Kranzler HR, Van Kirk J. Pharmacological treatments for alcohol use disorders. Expert Opinion on Pharmacotherapy. 2008;9(11):1927–39. 48. Krystal JH, Cramer JA, Krol WF, Kirk GF, Rosenheck RA; Veterans Affairs Naltrexone Cooperative Study 425 Group. Naltrexone in the treatment of alcohol dependence. N Engl J Med. 2001 Dec 13;345(24):1734–9. DOI: 10.1056/NEJMoa011127. PMID: 11742047 49. Bizzarri JV, Rucci P, Sbrana A, Miniati M, Raimondi F, Ravani L, Massei GJ, Milani F, Milianti M, Massei G, Gonnelli C, Cassano GB. Substance use in severe mental illness: self-medication and vulnerability factors. Psychiatry Res. 2009 Jan 30;165(1-2):88–95. DOI: 10.1016/j.psychres.2007.10.009. Epub 2008 Dec 2. PMID: 19054572 50. Gurevich GL. Psikhoterapiya v kompleksnom lechenii bol'nykh alkogol'noi zavisimost'yu s komorbidnoi endogennoi patologiei. Voprosy narkologii. 2019;1:67–73. (In Russ.) 51. Kholmogorova AB. Nauchnye osnovaniya i prakticheskie zadachi semeinoi psikhoterapii. Konsul'tativnaya psikhologiya i psikhoterapiya. 2002;2:78–94. (In Russ.) 52. Sinha R. The role of stress in addiction relapse. Curr Psychiatry Rep. 2007 Oct;9(5):388–95. DOI: 10.1007/s11920-007-0050-6. PMID: 17915078 53. Noordsy DL, Schwab B, Fox L, Drake RE. The role of self-help programs in the rehabilitation of persons with severe mental illness and substance use disorders. Community Ment Health J. 1996 Feb;32(1):71–81; discussion 83–6. DOI: 10.1007/BF02249369. PMID: 8635319 54. Drake RE, et al. Dual Diagnosis: Conceptual Model for Service Delivery. Psychiatric Services. 2001;52(4):469–75. 55. Winklbaur B, Ebner N, Sachs G, Thau K, Fischer G. Substance abuse in patients with schizophrenia. Dialogues Clin Neurosci. 2006;8(1):37–43. DOI: 10.31887/DCNS.2006.8.1/bwinklbaur. PMID: 16640112; PMCID: PMC3181760 56. Lappin JM. Comorbid substance use in psychosis: Someone else’s problem? Australian & New Zealand Journal of Psychiatry. 2021;56(1):5–7. DOI: 10.1177/00048674211065669 57. Meyer-Lindenberg A, Kolachana BS, Goldman AL. Neural mechanisms of genetic risk for impulsivity and violence in humans: a functional MRI study of the COMT gene polymorphism in healthy volunteers. Journal of Neuroscience. 2006;26(24):6228–33. 58. Rolland B, Jardri R, Amad A. Pharmacology of Hallucinations: Several Mechanisms for One Single Symptom? BioMed Research International. 2014. DOI: 10.1155/2014/307106 59. Bersani G, et al. Cannabis and schizophrenia: impact on onset, course, psychopathology and outcomes. European Archives of Psychiatry and Clinical Neuroscience. 2012;262:117–23. 60. Goffman E. Asylums: Essays on the Social Situation of Mental Patients and Other Inmates. New York: Anchor Books; 1961. 61. Rafi zadeh R. Effects of clozapine treatment on the improvement of substance use disorders other than nicotine in individuals with schizophrenia spectrum disorders: A systematic review and meta-analysis. Journal of Psychopharmacology. 2022. DOI: 10.1177/02698811221142575 62. Stephen Rich J, Martin PR. Co-occurring psychiatric disorders and alcoholism. Handb Clin Neurol. 2014;125:573–88. DOI: 10.1016/B978-0-444-62619-6.00033-1. PMID: 25307597 63. Buckley PF. Prevalence and consequences of the dual diagnosis of substance abuse and severe mental illness. J Clin Psychiatry. 2006;67(Suppl 7):5–9. PMID: 16961418

Метрики статей

Загрузка метрик ...

Metrics powered by PLOS ALM